Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care

Jill A. BellMillennium Pharmaceuticals, Inc, (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, MA, USA; Correspondence[email protected]
View further author information

Aaron GalaznikMillennium Pharmaceuticals, Inc, (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, MA, USA; View further author information

Marlo BlazerXcenda, LLC, Palm Harbor, Florida, USAView further author information

Eileen FarrellyXcenda, LLC, Palm Harbor, Florida, USAView further author information

Augustina OgbonnayaXcenda, LLC, Palm Harbor, Florida, USAView further author information

Aditya RajuXcenda, LLC, Palm Harbor, Florida, USAView further author information

Michael EaddyXcenda, LLC, Palm Harbor, Florida, USAView further author information

Robert J. FramMillennium Pharmaceuticals, Inc, (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, MA, USA; View further author information

Douglas V. FallerMillennium Pharmaceuticals, Inc, (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, MA, USA; View further author information

show all

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

John Paul Yun, Philip Q. Ding, Aastha Dolley & Winson Y. Cheung. (2023) Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada. Current Oncology 30:9, pages 8005-8018.
Crossref

Amer M Zeidan, Aristoteles Giagounidis, Mikkael A Sekeres, Zhijian Xiao, Guillermo F Sanz, Marlies Van Hoef, Fei Ma, Sabine Hertle & Valeria Santini. (2023) STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future Oncology 19:9, pages 631-642.
Crossref

Ken Hasegawa, Andrew H Wei, Guillermo Garcia-Manero, Naval G Daver, Nishanthan Rajakumaraswamy, Shahed Iqbal, Rebecca J Chan, Hao Hu, Preston Tse, Jiajun Yan, Michael J Zoratti, Feng Xie & David A Sallman. (2023) Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis. Clinical Lymphoma Myeloma and Leukemia 23:2, pages 127-137.
Crossref

Joshua F. Zeidner, Flora Mazerolle, Jonathan Norton, Antoine Regnault, Fjoralba Kristo, Heather Romero, Robert J. Fram, Douglas V. Faller, Mehul Dalal, Lionel Ades & Mikkael A. Sekeres. (2022) Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes. Haematologica 108:4, pages 1196-1199.
Crossref

Lionel Adès, Larisa Girshova, Vadim A. Doronin, María Díez-Campelo, David Valcárcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Sharon Friedlander, Douglas V. Faller & Mikkael A. Sekeres. (2022) Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Advances 6:17, pages 5132-5145.
Crossref

Saaya Tsutsué, Takahiro Suzuki, Hyojin Kim & Bruce Crawford. (2022) Real-world assessment of myelodysplastic syndrome: Japanese claims data analysis. Future Oncology 18:1, pages 93-104.
Crossref

Mayra Braga Lemos, Sarah Ramalho Rodrigues, Thomas Schroeder, Austin G. Kulasekararaj, Joana E. Matos & Derek Tang. (2021) Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta‐analysis. European Journal of Haematology 107:1, pages 3-23.
Crossref

Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care

Citations (7)

Articles from other publishers (7)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date